Clinical Trials
73
Active:0
Completed:50
Trial Phases
3 Phases
Phase 1:60
Phase 2:9
Phase 3:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (73 trials with phase data)• Click on a phase to view related trials
Phase 1
60 (82.2%)Phase 2
9 (12.3%)Phase 3
4 (5.5%)ADME Study of [14C] Yiqibuvir in Healthy Male Subjects
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT05998304
- Locations
- 🇨🇳
Shanghai xuhui central hospital, Shanghai, Shanghai, China
A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China
Phase 3
Not yet recruiting
- Conditions
- Diabetes
- Interventions
- Drug: Insulin Degludec and Insulin Aspart
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 408
- Registration Number
- NCT05802862
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Phase 3
Recruiting
- Conditions
- Leukemia, Acute Myeloid (AML)
- Interventions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 324
- Registration Number
- NCT05586074
- Locations
- 🇨🇳
the First Affiliated Hospital,College of Medicine,Zhejiang University, Hanzhou, China
A Clinical Study Comparing the Pharmacokinetics and Pharmacodynamic Characteristics of Insulin Degludec Injection (RD15003) and Insulin Degludec Injection (Tresiba®) in Healthy Subjects
Phase 1
Completed
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2022-10-12
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 46
- Registration Number
- NCT05576298
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Pharmacokinetics of Midazolam When Co-administered With HEC74647 and HEC110114
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- First Posted Date
- 2022-08-17
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT05504876
- Locations
- 🇨🇳
First Hospital of Jilin University, Changchun, Jilin, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 15
- Next
News
No news found